These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16487476)

  • 1. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations.
    Johnston MJ; Semple SC; Klimuk SK; Edwards K; Eisenhardt ML; Leng EC; Karlsson G; Yanko D; Cullis PR
    Biochim Biophys Acta; 2006 Jan; 1758(1):55-64. PubMed ID: 16487476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a stable single-vial liposomal formulation for vincristine.
    Mao W; Wu F; Lee RJ; Lu W; Wang J
    Int J Nanomedicine; 2019; 14():4461-4474. PubMed ID: 31296986
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity.
    Semple SC; Leone R; Wang J; Leng EC; Klimuk SK; Eisenhardt ML; Yuan ZN; Edwards K; Maurer N; Hope MJ; Cullis PR; Ahkong QF
    J Pharm Sci; 2005 May; 94(5):1024-38. PubMed ID: 15793796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage?
    Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
    J Pharm Sci; 2011 Jul; 100(7):2835-48. PubMed ID: 21305545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention.
    Zhigaltsev IV; Maurer N; Akhong QF; Leone R; Leng E; Wang J; Semple SC; Cullis PR
    J Control Release; 2005 May; 104(1):103-11. PubMed ID: 15866338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
    Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
    J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
    Krishna R; Webb MS; St Onge G; Mayer LD
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin.
    Johnston MJ; Semple SC; Klimuk SK; Ansell S; Maurer N; Cullis PR
    Biochim Biophys Acta; 2007 May; 1768(5):1121-7. PubMed ID: 17321495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.
    Sapra P; Moase EH; Ma J; Allen TM
    Clin Cancer Res; 2004 Feb; 10(3):1100-11. PubMed ID: 14871990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer.
    Webb MS; Logan P; Kanter PM; St-Onge G; Gelmon K; Harasym T; Mayer LD; Bally MB
    Cancer Chemother Pharmacol; 1998; 42(6):461-70. PubMed ID: 9788572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
    Li C; Cui J; Li Y; Wang C; Li Y; Zhang L; Zhang L; Guo W; Wang J; Zhang H; Hao Y; Wang Y
    Eur J Pharm Sci; 2008 Aug; 34(4-5):333-44. PubMed ID: 18573336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine.
    Webb MS; Saxon D; Wong FM; Lim HJ; Wang Z; Bally MB; Choi LS; Cullis PR; Mayer LD
    Biochim Biophys Acta; 1998 Jul; 1372(2):272-82. PubMed ID: 9675310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation, characterization, and biological analysis of liposomal formulations of vincristine.
    Waterhouse DN; Madden TD; Cullis PR; Bally MB; Mayer LD; Webb MS
    Methods Enzymol; 2005; 391():40-57. PubMed ID: 15721373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading.
    Abraham SA; McKenzie C; Masin D; Ng R; Harasym TO; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Jan; 10(2):728-38. PubMed ID: 14760096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations.
    Johnston MJ; Edwards K; Karlsson G; Cullis PR
    J Liposome Res; 2008; 18(2):145-57. PubMed ID: 18569449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stable and sustained release liposomal formulations of celecoxib: In vitro and in vivo anti-tumor evaluation.
    Matbou Riahi M; Sahebkar A; Sadri K; Nikoofal-Sahlabadi S; Jaafari MR
    Int J Pharm; 2018 Apr; 540(1-2):89-97. PubMed ID: 29371019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models.
    Webb MS; Harasym TO; Masin D; Bally MB; Mayer LD
    Br J Cancer; 1995 Oct; 72(4):896-904. PubMed ID: 7547237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Designing a novel in vitro drug-release-testing method for liposomes prepared by pH-gradient method.
    Nakamura K; Yoshino K; Yamashita K; Kasukawa H
    Int J Pharm; 2012 Jul; 430(1-2):381-7. PubMed ID: 22525083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.